Jw Life Science Corp - Asset Resilience Ratio
Jw Life Science Corp (234080) has an Asset Resilience Ratio of 1.01% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 234080 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Jw Life Science Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Jw Life Science Corp asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Jw Life Science Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 234080 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩3.07 Billion | 1.01% |
| Total Liquid Assets | ₩3.07 Billion | 1.01% |
Asset Resilience Insights
- Limited Liquidity: Jw Life Science Corp maintains only 1.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jw Life Science Corp Industry Peers by Asset Resilience Ratio
Compare Jw Life Science Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
Annual Asset Resilience Ratio for Jw Life Science Corp (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Jw Life Science Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.66% | ₩2.11 Billion ≈ $1.43 Million |
₩318.21 Billion ≈ $215.64 Million |
+0.01pp |
| 2024-12-31 | 0.65% | ₩2.11 Billion ≈ $1.43 Million |
₩325.32 Billion ≈ $220.47 Million |
-2.53pp |
| 2023-12-31 | 3.18% | ₩8.13 Billion ≈ $5.51 Million |
₩255.84 Billion ≈ $173.38 Million |
-6.69pp |
| 2022-12-31 | 9.87% | ₩24.95 Billion ≈ $16.91 Million |
₩252.94 Billion ≈ $171.42 Million |
+9.79pp |
| 2021-12-31 | 0.07% | ₩155.05 Million ≈ $105.07K |
₩219.47 Billion ≈ $148.73 Million |
+0.06pp |
| 2015-12-31 | 0.01% | ₩10.32 Million ≈ $7.00K |
₩179.88 Billion ≈ $121.90 Million |
-- |
About Jw Life Science Corp
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed … Read more